Woodline Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Woodline Partners’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.5M	Buy	752,489 +181	+0%	+$5.96K	0.08%	316
2026 Q1	$24.1M	Buy	752,308 +1,038	+0.1%	+$33.8K	0.09%	293
2025 Q4	$26.4M	Sell	751,270 -406,597	-35%	-$14.8M	0.1%	256
2025 Q3	$32.9M	Sell	1,157,867 -739,330	-39%	-$17.7M	0.16%	185
2025 Q2	$34.4M	Sell	1,897,197 -545,200	-22%	-$9.94M	0.18%	157
2025 Q1	$50M	Buy	2,442,397 +11,615	+0.5%	+$258K	0.33%	83
2024 Q4	$62.5M	Buy	2,430,782 +1,266,105	+109%	+$26.9M	0.42%	53
2024 Q3	$19.3M	Buy	1,164,677 +681,289	+141%	+$11.8M	0.16%	196
2024 Q2	$9.29M	Buy	+483,388	New	+$9.7M	0.09%	257

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Woodline Partners's NAMS Position: Q2 2026 in Review

Woodline Partners increased its NewAmsterdam Pharma (NAMS) stake by 0.02% in Q2 2026, buying an estimated $5.96K and bringing the position to 752,489 shares worth $25.5M. The position accounts for 0.08% of the portfolio, ranked #316.

Woodline Partners first reported a position in NAMS in Q2 2024 and has held it in 9 quarters since. The position peaked at $62.5M in Q4 2024. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Woodline Partners held 752,489 shares of NewAmsterdam Pharma worth $25.5M as of Q2 2026.
Woodline Partners bought 181 NewAmsterdam Pharma shares in Q2 2026, an estimated $5.96K.
NewAmsterdam Pharma made up 0.08% of Woodline Partners's portfolio in Q2 2026, its #316 holding.
Woodline Partners first reported a position in NewAmsterdam Pharma in Q2 2024 and has held it in 9 quarters since.
Woodline Partners's NewAmsterdam Pharma position peaked at $62.5M in Q4 2024.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.